http://www.arraybiopharma.com/ http://finance.yahoo.com/q/ks?s=ARRY http://investorshub.advfn.com/boards/read_msg.asp?message_id=27628473 http://www.form4oracle.com/company?cik=0001100412&ticker=arry
Array BioPharma, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of targeted small molecule drugs to treat debilitating and life-threatening diseases. Its proprietary drug development pipeline primarily focuses on the treatment of cancer and inflammatory disease, and includes clinical candidates that are designed to regulate therapeutically important target proteins. The company's principal products include ARRY-886, which is an MEK inhibitor for cancer, and is in randomized phase II clinical trials in malignant melanoma; ARRY-543, an ErbB-2/EGFR inhibitor, which is in phase I clinical trials; ARRY-162, an MEK inhibitor for inflammation, which is in phase I clinical trials; ARRY-797, a p38 inhibitor; and ARRY-520, a KSP inhibitor. It has partnerships with Amgen, Inc.; AstraZeneca PLC; Genentech, Inc.; ICOS Corporation; InterMune, Inc.; Japan Tobacco, Inc.; Ono Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company, Ltd. The company was founded in 1998 and is headquartered in Boulder, Colorado.